![]() |
市场调查报告书
商品编码
1519735
2024-2032 年银伤口敷料市场报告(按类型、疾病、最终用户和地区)Silver Wound Dressing Market Report by Type, Disease, End User, and Region 2024-2032 |
IMARC Group年,全球银伤口敷料市场规模达到 9.701 亿美元。
银伤口敷料是指向伤口释放稳定量的银以提供抗菌和抗菌作用的局部伤口护理产品。它们以屏障层、木炭布敷料、泡棉敷料和水胶体的形式广泛使用。银敷料可用作主要或次要敷料,以处理急性和慢性伤口(例如手术伤口、烧伤、压疮、腿部溃疡和糖尿病足溃疡)中的少量、中度或大量渗出液。它们还可以在压迫下或与选定的局部和辅助疗法一起使用,以减少细菌负荷、抑制渗出物并改善伤口肉芽组织的外观。近年来,银伤口敷料在医疗保健产业中广受欢迎,用于治疗局部感染或生物负荷或有局部感染或生物负荷风险的急性或慢性伤口。
银伤口敷料有助于预防和减少感染,提供广泛的抗菌活性,并改变伤口内的金属蛋白酶。因此,银伤口敷料正在迅速取代传统的伤口护理和闭合产品,这是推动市场成长的主要因素。除此之外,慢性伤口和烧伤的发生率不断上升,以及人们对先进伤口护理治疗的认识不断增强,都刺激了对银伤口敷料的需求。此外,癌症、糖尿病和心血管疾病(CVD)等慢性病的盛行率显着增加。同时,越来越多的接受手术的患者鼓励采用银伤口敷料,以防止手术部位感染并促进伤口更快癒合。此外,一些主要参与者正在投入大量资金推出新型创新银伤口敷料变体,以扩大其产品组合併获得竞争优势。其他因素,包括家庭医疗保健的新兴趋势、道路事故案件的增加、人口老化、医疗基础设施的改善、技术进步以及广泛的研发(R&D)活动,也为市场成长提供了积极的推动力。
The global silver wound dressing market size reached US$ 970.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,386.7 Million by 2032, exhibiting a growth rate (CAGR) of 4% during 2024-2032.
Silver wound dressings refer to topical wound care products that release a steady amount of silver to the wound to provide antimicrobial and antibacterial action. They are widely available in the form of barrier layers, charcoal cloth dressings, foam dressings, and hydrocolloids. Silver dressings can be used as primary or secondary dressings to manage minimal, moderate, or heavy exudate in acute and chronic wounds, such as surgical wounds, burns, pressure ulcers, leg ulcers, and diabetic foot ulcers. They can also be utilized under compression or with select topical and adjunctive therapies to reduce the bacterial load, contain exudate, and improve the appearance of the wound's granulation tissue. In recent years, silver wound dressings have gained immense popularity in the healthcare industry to treat acute or chronic wounds with or at risk of local infection or bioburden.
Silver wound dressings help prevent and reduce infections, provide a wide range of antimicrobial activity, and alter metalloproteinases within wounds. As a result, silver wound dressings are rapidly replacing traditional wound care and closure products, which represents the primary factor driving the market growth. Besides this, the rising incidences of chronic wounds and burns and the growing awareness regarding advanced wound care treatment are catalyzing the demand for silver wound dressings. Additionally, there has been a significant increase in the prevalence of chronic conditions, such as cancer, diabetes, and cardiovascular diseases (CVDs). Along with this, the increasing number of patients undergoing surgeries is encouraging the adoption of silver wound dressings to prevent surgical site infections and promote faster wound healing. Furthermore, several key players are making heavy investments to launch new and innovative silver wound dressing variants to expand their product portfolio and gain a competitive edge. Other factors, including the emerging trend of home healthcare, rising cases of road accidents, aging population, improving healthcare infrastructure, technological advancements, and extensive research and development (R&D) activities, are also providing a positive thrust to the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global silver wound dressing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease and end user.
Hydrofiber Silver Dressings
Nanocrystalline Silver Dressing
Silver Plated Nylon Fiber Dressing
Silver Nitrate Dressing
Silver Alginate Dressing
Others
Ulcers
Burns
Cuts and Lacerations
Others
Inpatient Facilities
Outpatient Facilities
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Advanced Medical Solutions Group plc, B. Braun Melsungen AG, Cardinal Health Inc., Coloplast A/S, ConvaTec Group plc, Ferris Mfg. Corp., Hollister Incorporated, Integra LifeSciences, Medline Industries LP, Molnlycke Health Care AB and Smith & Nephew plc.